Longevity Health Holdings Inc. (Nasdaq: XAGE) has announced a definitive merger agreement with True Health Inc., operating under the THPlasma brand, in an all-stock transaction aimed at combining their operations. The merger, unanimously approved by the boards of both companies, is slated to close in the fourth quarter of 2025, subject to customary closing conditions. Post-closing, the combined entity will continue trading on Nasdaq under the symbol "XAGE." As part of the agreement, THPlasma is valued at $59 million, with an additional $20 million earnout based on financial performance, and Longevity stock is valued at $3.00. Leadership roles post-merger will see Mr. Rajiv Shukla serving as Executive Chairman, while Mr. George Chi will take on the roles of Co-Chairman and CEO.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.